NEW YORK (GenomeWeb News) – Leerink Swann analyst Isaac Ro said in a research report published today that he believes a major acquisition by Thermo Fisher Scientific is "likely in the near term, with possible targets coming in the areas of Bioprocess tools, HPLC, or Diagnostics."

He noted that Thermo's shares have lagged the market recently due to ongoing speculation about a major acquisition for the firm. Ro said that given Thermo's broad distribution channel, the company "could choose any of these areas and recognize material benefits."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.